Skip to main content

Advertisement

Table 1 Characteristics of patients in this study

From: Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment

  CD UC HS Indeterminate
n 121 75 27 8
Female gender (n) 59.5% (72) 49.3% (37) 55.6% (15) 62.5% (5)
Age (lower 95%-upper 95%) 37.3 (34.3-40.3) 41.1 (37.4-44.9) 35.1 (29.1-41.2) 26.9 (13.4-40.3)
Smoker (n)     
   Never 63.6% (77) 57.3% (43) 85.2% (23) 75.0% (6)
   Previously 24.8% (30) 40% (30) 11.1% (3) 12.5% (1)
   Current 10.7% (13) 2.7% (2) 0% (0) 12.5% (1)
   Unknown 0.8% (1) 0% (0) 3.7% (1) 0% (0)
Sample     
   Stool (n) 51.2% (62) 64% (48) 66.7% (18) 100% (8)
   Biopsy (n) 48.8% (59) 36% (27) 33.3% (9) 0% (0)
Disease     
   Active disease (n)a 26.4% (32) 29.3% (22) 0% (0) 0% (0)
   Ileal (n) 35.5% (43) NA NA NA
Treatment     
   Mesalamine (n) 55.4% (67) 77.3% (58) 0% (0) 75.0% (6)
   Steroids (n) 31.4% (38) 37.3% (28) 0% (0) 50% (4)
   Immunosuppressant (n)b 38.8% (47) 16% (12) 0% (0) 0% (0)
   Antibiotics (n) 12.4% (15) 13.3% (10) 0% (0) 12.5% (1)
  1. aActive disease defined by a Harvey-Bradshaw Index (HBI) ≥ 5 or Pediatric Crohn's Disease Activity Index (pCDAI) ≥ 10 for Crohn's disease (CD), and Simple Clinical Colitis Activity Index ≥ 5 or Pediatric Ulcerative Colitis Activity Index (pUCAI) ≥ 10 for ulcerative colitis (UC). bImmunosuppressant treatments include thiopurines, methotrexate, and anti-tumor necrosis factor-α antibody. HS, healthy subjects; NA, not applicable.